In September (2018) ImmusanT announced first patient dosed in Phase 2 Trial of the Nexvax2 vaccine, the only disease-modifying therapeutic candidate in clinical development for patients with celiac.
LiveScience.com recently wrote an article describing how this vaccine works. “An experimental “vaccine” for celiac disease is set to be tested in a new clinical trial to see if the treatment can protect patients with the condition from the effects of eating gluten — or, in other words, allow those patients to eat gluten safely.
The treatment, called Nexvax2 and made by the biotech company ImmusanT Inc., is a type of immunotherapy that aims to “reprogram” the immune system to be tolerant of gluten, the researchers said.” Read more here
Check out ImmusanT Press Release: October 30, 2018
